News

Article

FDA Issues Guidance on Evaluation of Drug Toxicity

The agency releases guidance on the nonclinical evaluation of endocrine-related drug toxicity.

 

On Sept. 8, 2015, FDA issued recommendations to sponsors of investigational new drug applications, new drug applications, and biologics license applications regarding nonclinical studies performed to identify potential endocrine-related toxicity. The guidance describes how endocrine-related toxicity is assessed and identifies when additional studies should be considered. The guidance is specific to nonclinical testing “designed to assess the potential for a drug to cause endocrine effects that are unintentional and adverse,” and does not provide guidance relating to “development of drugs that are intended to interfere with the endocrine system to prevent or treat a particular disease or condition, and it does not provide detailed recommendations regarding clinical studies to investigate adverse endocrine-related activity.” The guidance does not cover environmental assessment issues.

Source: FDA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content